A Case Report: Long Post-COVID Vaccination Syndrome During the Eleven Months After the Third Moderna Dose.

adverse reaction long post-covid vaccination syndrome neuro-cognition sars-cov-2 vaccination side effects

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Dec 2022
Historique:
accepted: 12 12 2022
entrez: 16 1 2023
pubmed: 17 1 2023
medline: 17 1 2023
Statut: epublish

Résumé

It is undisputed that anti-SARS-CoV-2 vaccines can have side effects. Long post-COVID vaccination syndrome (LPCVS) is one of them and is often neglected. It persists 11 months after the third mRNA-1273 (Moderna) vaccine dose has not been reported. Our patient is a 39-year-old male with a largely uneventful previous history who developed severe adverse reactions immediately after the third dose of the mRNA-1273 (Moderna) vaccine. In addition to brief fever, headache, flickering eyes, skin rashes, tiredness, disorientation, dizziness (brain fog), tiredness, impaired thinking and concentration, and emotional disorders occurred as a result. Cerebral MRI showed non-specific white matter lesions in a frontotemporal distribution. Some of the immune parameters were deflected. Non-steroidal anti-inflammatory drugs, antihistamines, sartans, and statins have occasionally provided temporary relief. In conclusion, LPCVS is a definite complication of anti-SARS-CoV-2 vaccinations and can severely impact the quality of life and lead to disability. Despite extensive work-up, a clear cause for the long-term neuro-cognitive deficits cannot be identified. Symptomatic treatment can provide some relief. Patients with LPCVS should be taken seriously and treated appropriately.

Identifiants

pubmed: 36644105
doi: 10.7759/cureus.32433
pmc: PMC9833629
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e32433

Informations de copyright

Copyright © 2022, Finsterer et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Biol Regul Homeost Agents. 2020 Oct 5;34(5):1633-1636
pubmed: 33023287
Food Chem Toxicol. 2022 Jun;164:113008
pubmed: 35436552
Cureus. 2021 Jun 15;13(6):e15664
pubmed: 34277256
Annu Rev Med. 2022 Jul 18;:
pubmed: 35850494
IDCases. 2022 Jul 13;29:e01563
pubmed: 35855938
Allergy Asthma Proc. 2022 Jan 1;43(1):30-36
pubmed: 34983707
Mol Neurobiol. 2022 Mar;59(3):1850-1861
pubmed: 35028901
PLoS One. 2022 Feb 22;17(2):e0264323
pubmed: 35192657
Cureus. 2022 Jan 18;14(1):e21376
pubmed: 35198288
Rechtsmedizin (Berl). 2022 Jul 20;:1-7
pubmed: 35873498
Clin Infect Dis. 2022 Jun 10;74(11):1933-1950
pubmed: 34406358
Trends Mol Med. 2022 Jul;28(7):542-554
pubmed: 35537987
Vaccines (Basel). 2021 Nov 17;9(11):
pubmed: 34835275
Vaccine. 2022 Sep 22;40(40):5798-5805
pubmed: 36055877
J Clin Transl Res. 2022 Nov 09;8(6):506-508
pubmed: 36452006
Pathologica. 2022 Aug;114(4):322-325
pubmed: 36136900
Front Med (Lausanne). 2022 Oct 10;9:933914
pubmed: 36300183

Auteurs

Josef Finsterer (J)

Neurology, Neurology and Neurophysiology Center, Vienna, AUT.

Classifications MeSH